Impact of specialist management on survival from radiation‐associated angiosarcoma of the breast.
Published: 6th February 2018
Authors: L. Feinberg, A. Srinivasan, J. K. Singh, M. Parry, J. Stevenson, L. Jeys et al.
Radiation‐associated angiosarcoma of the breast (RAAS) is a rare complication of adjuvant radiotherapy associated with poor survival. The British Sarcoma Group guidelines recommend that all angiosarcomas are referred to a sarcoma multidisciplinary team, although there is no recommendation that patients are managed within a sarcoma service. The aims of this study were to compare survival, complete excision rates and local recurrence rates of patients managed within a sarcoma service and those managed within local hospitals.
All patients with RAAS referred to a regional sarcoma service between 1998 and 2015 were identified from prospective databases. Patient records, and radiology, pathology and operation notes were reviewed retrospectively.
Thirty‐six patients were operated on with curative intent; 26 were managed by the sarcoma service (of whom 21 underwent radical excision of the irradiated field followed by chest wall reconstruction) and ten were managed locally. Median age was 69·5 (range 43–85) years. Disease‐specific survival was significantly longer in patients managed by the sarcoma service than in those managed locally: median 91·1 (range 69·2–113·0)
Specialist management of RAAS leads to fewer local recurrences and improved disease‐specific survival. Early referral and management within specialist units is recommended.Read more
You may also be interested in
Authors: Z. E. Winters, J. R. Benson
Authors: M. A. Stammes, S. L. Bugby, T. Porta, K. Pierzchalski, T. Devling, C. Otto et al.
Notes: Visible results
Authors: P. McAnena, A. Lowery, M. J. Kerin
Notes: Promising technology
Minimizing inequality in access to precision medicine in breast cancer by real‐time population‐based molecular analysis in the SCAN‐B initiative. BJS 2018; 105: e158-e168.
Authors: L. Rydén, N. Loman, C. Larsson, C. Hegardt, J. Vallon‐Christersson, M. Malmberg et al.
Notes: Promising Swedish initiative
MiR‐128 regulation of glucose metabolism and cell proliferation in triple‐negative breast cancer. BJS 2018; 105: 75-85.
Authors: M. Xiao, C. Lou, H. Xiao, Y. Yang, X. Cai, C. Li et al.
Notes: New molecular target?
International validation of the European Organisation for Research and Treatment of Cancer QLQ‐BRECON23 quality‐of‐life questionnaire for women undergoing breast reconstruction. BJS 2018; 105: 209-222.
Authors: Z. E. Winters, M. Afzal, C. Rutherford, B. Holzner, G. Rumpold, R. A. da Costa Vieira et al.
Notes: Useful tool
Axillary tumour burden in women with a fine‐needle aspiration/core biopsy‐proven positive node on ultrasonography compared to women with a positive sentinel node. BJS 2017; 104: 1811-1815.
Authors: P. Lloyd, E. Theophilidou, R. G. Newcombe, L. Pugh, A. Goyal
Notes: Axillary ultrasound can detect low‐volume metastases
Superparamagnetic iron oxide nanoparticles as the sole method for sentinel node biopsy detection in patients with breast cancer. BJS 2017; 104: 1675-1685.
Authors: A. Karakatsanis, K. Daskalakis, P. Stålberg, H. Olofsson, Y. Andersson, S. Eriksson et al.
Notes: Simplifies logistics
Authors: M. Ahmed, M. Douek
Risk of death from breast cancer after treatment for ductal carcinoma in situ. BJS 2017; 104: 1506-1513.
Authors: C. Wadsten, H. Garmo, I. Fredriksson, M. Sund, F. Wärnberg
Notes: Rare, but worse for large tumours and uncertain margins
Improved prognosis of young patients with breast cancer undergoing breast‐conserving surgery. BJS 2017; 104: 1802-1810.
Authors: E. Botteri, P. Veronesi, J. Vila, N. Rotmensz, V. Galimberti, M. V. Thomazini et al.
Notes: Molecular subtype matters most
Authors: R. N. Pedersen, K. Bhaskaran, U. Heide‐Jørgensen, M. Nørgaard, P. M. Christiansen, N. Kroman et al.
Notes: No correlation